Inovio Biomedical Corporation (AMEX: INO)Inovio Biomedical Corporation (AMEX: INO) has their focus on developing multiple DNA-based immunotherapies. The company is known as a leading developer of human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Inovio’s DNA delivery technology has demonstrated the ability to substantially increase gene expression and immune responses from DNA vaccines. For further information, visit the Company’s web site at www.inovio.com.
- 18 years ago
QualityStocks
Inovio Biomedical Corporation (AMEX: INO)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Frontieras North America Inc. Advancing FASForm(TM) for Domestic, Feedstock-Driven Energy Production
Frontieras is positioned amid increased demand for domesticenergy production. “At the core of its strategy is…
-
LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Expands Gold Asset Portfolio in Abitibi Supporting Mine-to-Mill Platform
Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid…
-
American Fusion(TM) Inc. (AMFN) Expands into Government Procurement While Advancing Fusion Energy Development
American Fusion(TM) launched a Government Procurement Services segment alongside its fusion energy development business. The…